



**PURPOSE:** The purpose of this policy is to identify patients in the Infectious Disease Center (IDC) who may receive Cabenuva

**I. PERSONS AFFECTED:** IDC physicians, staff nurses, administrative staff, pharmacists, patients.

**II. DEFINITIONS:** Cabenuva: cabotegravir/rilpivirine (CAB/RPV)

**III. PROCEDURE:**  
**Cabenuva (cabotegravir/rilpivirine) IM injection**

The IDC physician will ascertain the patient meets the following criteria prior to consulting the pharmacy team to initiate investigation in to access of Cabenuva:

- Have no baseline resistance to either medication
- Have no prior virologic failures
- Not have active hepatitis B virus (HBV) infection (unless also receiving an oral HBV active regimen)
- Not be pregnant or planning to become pregnant
- Not be taking medications with significant drug interactions with oral (during lead-in or bridging therapy) or injectable cabotegravir or rilpivirine
  - PPIs, H2 antagonists, rifamycins, anticonvulsants, etc
- Stable on current antiretroviral treatment for  $\geq 12$  months
- Have had an appointment with an IDC physician within the past 12 months
- No previous “No Show” to appointment with IDC physician within the past 18 months

If patient meets criteria the physician will send a message to IDC pharmacy pool to initiate request for investigation into treatment with Cabenuva. Before investigation can occur the following must be completed:

- Specific documentation in patient’s chart by physician listing potential regimen change (cannot state “continue medications as above)
- Patient meets with pharmacy team for initial education
  - Recommended to be in person to sign adherence agreement
- Contract of adherence to monthly IDC visits signed by patient (blank contracts located within pharmacist office)

Once all above criteria met and consult received following will occur:

- Pharmacist will add patient to Epic list
- IDC pharmacist to contact ViiV to begin process of obtaining oral lead in therapy from ViiV Hub and determine if patient will receive medication through pharmacy or medical insurance

- If pharmacy insurance, pharmacist to send e-script for medication to Northwestern Medicine Specialty Pharmacy (NMSP)
- If medical insurance (i.e., buy and bill) pharmacist will place order through 9Rx
  - Pharmacist to communicate with store room to ensure supply
- Patient to receive oral supply of CAB and RPV via ViiV connect

#### Administration schedule:

- Oral lead-in of CAB 30 mg plus RPV 25 mg once daily with food for at least 28 days before beginning the IM injections
- First IM injections should be administered on the last day of oral therapy with a loading dose of CAB 600 mg (3 mL) and RPV 900 mg (3 mL)
  - Given as two separate injections in separate ventrogluteal sites
- Continuation therapy with monthly CAB 400 mg (2 mL) and RPV 600 mg (2 mL)
  - Given as two separate ventrogluteal IM injections
  - Begins thereafter with a +/- 7-day administration window

#### Administration logistics:

- Pharmacist will coordinate last day of oral lead in with patient and send a message to Admin Pool to schedule the patient for a nurse visit on a specific date/time
  - Pharmacist to check nurse visit schedule to ensure availability
- Patient list will be checked each day by the pharmacist
  - Alert clinic staff if pick up from 9Rx (for buy and bill)
    - For 9Rx, next day's supply will be picked up
    - Once labeled medication arrives will store in fridge in ID clinic clean utility room
  - Pharmacist delivery from NMSP (for pharmacy benefits)
    - Medication to be delivered daily
    - Once labeled medication arrives will store in fridge in ID clinic clean utility room
- Medication should not be removed from the fridge until the patient is checked-in
- Before preparing the injections, remove Cabenuva from the refrigerator and wait at least 15 minutes to allow the medicines to come to room temperature.
  - The vials may remain in the carton at room temperature for up to 6 hours.
    - Medication must be discarded if not used within 6 hours
    - Medication may not be returned to the fridge after removal
- Patient required to have at least 1 scheduled injection appointment before leaving clinic
  - Complete during check-out period to avoid patient leaving without future appointment
  - Remind patient after injection to schedule next appointment
- Pharmacist to monitor list for no-show appointments
  - Pharmacist to call patient to reschedule
  - If unable to contact patient x3, letter will be sent
- Medication kit may be returned if not opened and not removed from fridge

If patient misses appointment for injection (unplanned):

- Pharmacist to call patient x 3 and attempt to schedule within next week of missed appointment, letter sent if unable to contact
- Pharmacist to send MyChart message to patient
- If unable to schedule within a week period (dependent upon clinical factors)
  - Refill of previous oral therapy sent to patient's preferred pharmacy and patient removed from Cabenvua protocol

If patient misses appointment for injection (planned):

- Patient to receive oral medications from Theracomm for up to 2 months
- Pharmacist to schedule next injection as soon as possible

**V. PROCEDURE UPDATE SCHEDULE:**

This procedure will be reviewed every three years or unless practice changes.

**Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP**

System-Level HIV/ID Clinical Pharmacist  
Ambulatory Pharmacy  
Northwestern Medicine

26W171 Roosevelt Rd  
Building B Ground Level  
Wheaton, IL 60187

630.933.5054 office  
312.250.1075 pager  
[milgriff@nm.org](mailto:milgriff@nm.org)